🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great to present this secondary analysis of a prospective randomized trial at SABCS showing decreased acute toxicity with VMAT vs 3D-CRT technique for patients with breast cancer receiving PMRT/RNI. An important treatment option for our patients! MD Anderson Cancer Center SABCS

Presented at #SABCS24: The INSEMA randomized trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results: nej.md/41o5L0Z

Presented at #SABCS24: Interim results from the EUROPA trial: Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer thelancet.com/journals/lanon…

Exciting COM trial results- Active Monitoring of low risk DCIS does not lead to higher rates of Invasive cancer in 2years compared to surgery. Shelley Hwang #SABCS24 Duke Surgery Alliance for Clinical Trials in Oncology jamanetwork.com/journals/jama/…

Rapid Fire 2 #SABC24 ➡️ Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO) ☢️ OncoAlert #OncoAlertAF

Clinical Controversies #SABC24 ✨ Omission of Axillary Staging in ER Positive Breast Cancer : Implications on Adjuvant Therapies ➡️ Omission of Axillary Staging in ER+ Disease What is The Data? OncoAlert #OncoAlertAF

📌 Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies Topic 1: Omission of Axillary Staging in ER+ Disease – What is The Data? by Dr. E Mittendorf Dana-Farber’s Breast Oncology Center #SABCS24 #day3 OncoAlert #OncoAlertAF

Single-modality endocrine therapy versus #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #BreastCancer (EUROPA) The Lancet Oncology ▶️ Share Link – 50 days' free access to the article (Jan 31, 2025): authors.elsevier.com/a/1kFkd5EIIgPe…

Congrats to our eContour & MIM Software Travel Award Winners for #ACRO2025!

✨The New Year is upon us! ✨ Join an amazing new crew in the new year by applying for our Associate Editor position! Application is due January 17th! Just ask Leah D'Souza, MD, MSc JeremyPrice MDPhD Yasamin Sharifzadeh, MD Parisa Shams Lakshmi R Narra docs.google.com/forms/d/e/1FAI…

👏👏👏Very encouraging (and expected) results! Congrats to the authors for this endeavor that will undoubtedly benefit a large patient population! However, I'd think the AEs related to RT would be much lower, if assessed slightly differently, since we would not expect, for

Dissemination and Implementation – A Primer for Accelerating “Time to Translation” in Radiation Oncology by Erin Gillespie, MD MPH #RedJournal #radonc tinyurl.com/redgill1

Application due 1/31 for this amazing training opportunity funded by NCI. mskcc.org/departments/me…

📜 Led by Dr Kaitlyn Lapen in The Lancet Oncology, we discuss implementation of and response to #ePRO collection for patients on CAR T-cell therapies 🙏 Thank you to Drs @Erin_Feliciano Erin Gillespie, MD MPH @Joachim_Yahalom @Brandon_Imber ! 🔗 thelancet.com/journals/lanon…

At the #NRG2025 NCORP Townhall, we'll hear updates about NRG's #NCORP Program, how a leading #NCORP site is successful in #clinicaltrial enrollment, FORTE Study, new study NRG-CC014 & NCI NCORP & CCDR. Deborah W. Bruner lisa kachnic Jeffrey M Dueker, MD, MPH Erin Gillespie, MD MPH National Cancer Institute

👏Excellent talk by Jun J. Mao on integrative oncology - from building evidence to precision medicine. Great partnership w/ survivor Frank Licciardi - "the journey is not binary living or dying." 👀Look out for a recording from National Cancer Institute OCS Director Series led by Dr Emily Tonorezos.

Announcing NRG-CC014 (PREEMPT) by Dr. Gillespie! 📢 A Phase 3 trial exploring radiation therapy for high-risk asymptomatic bone metastases. A step forward in innovative cancer care! Erin Gillespie, MD MPH #radonc NRG Oncology RTOG Foundation #NRG2025

#bestteaminmedicine is ranked top 10 again. MUSC Hollings Cancer Center Medical University of South Carolina (MUSC)

My superstar colleague ⁦Erin Gillespie, MD MPH⁩ presented her new ⁦NRG Oncology⁩ phase 3 RCT as PI ⁦NRG Oncology⁩ winter meeting in Phoenix. Please consider opening the trial when it’s activated. ⁦Fred Hutch Cancer Center⁩ ⁦University of Washington Radiation Oncology⁩

Protocol Activation! NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) is now open to patient entry. Erin Gillespie, MD MPH University of Washington Radiation Oncology Fred Hutch Cancer Center Perlmutter Cancer Center at NYU Langone Health National Cancer Institute